Chinese regulator cracks down on illegal Botox distribution

Local media such as Xinhua News Agency, Cooperate with NMPA , to withdraw from unauthorized cosmetic procedures

Representative domestically-produced botulinum toxin regulated items

Chinese regulators are expected to strengthen crackdowns on unauthorized procedures in the local medical and beauty market, effectively blocking exports of illegal botulinum toxins to China.

 

According to the Chinese media, Xinhua, etc.

 

on the 15th, the public security authorities said they would strictly crack down on illegal activities related to unauthorized procedures in the Chinese medical and beauty market.

 

It is understood that in China, the treatment of illegally distributed drugs causes fatal side effects to patients, as well as frequent medical disputes.

 

It is known that the National Medical Products Administration (NMPA), Ministry of Culture of the People's Republic of China, and the Cyber ​​Investigation Unit are working together to block the distribution of unauthorized and illegal drugs.

 

The Chinese medicine, medical device, and beauty product market is divided into institutional products that have been approved by the NMPA and the gray market distributed by Daigong.

 

According to Article 418 of the Drug Administration Act of the People's Republic of China, all drugs used in China must be approved in accordance with the laws of the Chinese government, and it is illegal if they are sold without obtaining permission for production or import.

 

The Yanzhi economy in China is attracting attention as a new consumption trend.

 

It refers to consumption activities related to appearance, such as plastic surgery, surgery, and cosmetics.

 

With the spread of the trend, the establishment of illegal medical institutions and the distribution of illegal drugs are also increasing.

 

Korea's botulinum toxin is the number one target for such regulation and management, and more attention and attention are being paid to it.

 

A domestic industry official predicted that "Letybo is the only botulinum toxin product that has been officially licensed by the NMPA.

 

Some companies that are estimated to have distributed the product to China through Daigong will suffer much damage." In October 2019, China's national broadcaster CCTV2 reported that the MFDS issued an order to forcibly collect and dispose of many of the botulinum toxin products exported to China by domestic parent companies.

 

At the time, CCTV2 said, "The test report data of this company's product was manipulated, and the lot number that was discarded due to defects was changed to the normal lot number.

 

Products with unstable medicinal effects were distributed." It is sold without a registration permit from the China Pharmaceutical Supervisory Service and requires a lot of attention from consumers." Another industry insider said, “Unauthorized distribution of Korean botulinum toxin products in China is an offense that undermines market order and destroys the status of K-Toxin and K-Bio.

 

Exporting to China through illegal distribution channels is prohibited.

 

It's time to find a solution to eradicate it."